Acquisition of the ACCEL cell therapy platform through the acquisition of Xyphos
A theme focused on acquiring Xyphos as a wholly owned subsidiary to obtain its proprietary ACCEL™ cell therapy technology platform for cancer immunotherapy, with the aim of combining it with existing regenerative and cell therapy capabilities.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.